1. Lee K, Enns EA,
Drekonja D. Selecting appropriate antibiotic
prophylaxis for trans-rectal prostate biopsy
in an era of increasing antimicrobial
resistance. Value in Health. 2018
Mar;21(3):310-317. doi:
10.1016/j.jval.2017.08.3016. Epub 2017 Oct.
18
2. Pollom EL, Lee K,
Durkee BY, Grade M1, Mokhtari DA, Wahl DR,
Feng M, Kothary N, Koong AC, Owens DK,
Goldhaber-Fiebert J, Chang DT.
Cost-effectiveness of Stereotactic Body
Radiation Therapy versus Radiofrequency
Ablation for Hepatocellular Carcinoma: A
Markov Modeling Study. Radiology. 2017 Jan.
3:161509. doi: 10.1148/radiol.2016161509
3. Campos NG, Sharma M,
Clark A, Lee K, Geng F, Regan C, Kim
JJ, Resch S. The Health and Economic Impact
of Scaling Cervical Cancer Prevention in 50
Low- and Lower-Middle Income Countries.
American Cancer Society report Int J
Gynaecol Obstet. 2017 Jul.;138 Suppl
1:47-56. doi: 10.1002/ijgo.12184
4. Campos NG, Tsu V,
Jeronimo J, Mvundura M, Lee K, Kim
JJ. To Expand Coverage, or Increase
Frequency: Quantifying the Tradeoffs between
Equity and Efficiency Facing Cervical Cancer
Screening Programs in Low-Resource Settings.
Int J Cancer. 2017 Mar 15;140(6):1293-1305.
doi: 10.1002/ijc.30551
5. Campos NG, Sharma M,
Clark A, Lee K, Geng F, Kim JJ,
Resch S. Comprehensive Global Cervical
Cancer Prevention Costs and Benefits of
Scaling up within a Decade, American Cancer
Society, 2016
6. Burger EA, Lee K,
Saraiya M, Thompson TD, Chesson HW,
Markowitz LE, Kim JJ. Racial and ethnic
disparities in human
papillomavirus-associated cancer burden with
first-generation and second-generation human
papillomavirus vaccines. Cancer. 2016 Jul.
1;122(13):2057-66. doi: 10.1002/cncr.30007.
Epub 2016 Apr 28.
7. Campos NG, Tsu V,
Jeronimo J, Mvundura M, Lee K, Kim
JJ. When and how often to screen for
cervical cancer in three low- and
middle-income countries: A
cost-effectiveness analysis. Papillomavirus
Research, 2015 Dec.
https://doi.org/10.1016/j.pvr.2015.05.003